PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented represents Part I of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. MATERIALS AND METHODS: The systematic review utilized in the creation of this guideline was completed by the Agency for Healthcare Research and Quality and through additional supplementation by ECRI Institute. This review included articles published between January 2007 and March 2014 with an update search conducted through August 2016. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. Additional information is provided as Clinical Principles and Expert Opinions (table 2 in supplementary unabridged guideline, http://jurology.com/). RESULTS: The AUA (American Urological Association), ASTRO, and SUO (Society of Urologic Oncology) formulated an evidence-based guideline based on a risk stratified clinical framework for the management of localized prostate cancer. CONCLUSIONS: This guideline attempts to improve a clinician's ability to treat patients diagnosed with localized prostate cancer, but higher quality evidence in future trials will be essential to improve the level of care for these patients. In all cases, patient preferences should be considered when choosing a management strategy.
PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented represents Part I of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. MATERIALS AND METHODS: The systematic review utilized in the creation of this guideline was completed by the Agency for Healthcare Research and Quality and through additional supplementation by ECRI Institute. This review included articles published between January 2007 and March 2014 with an update search conducted through August 2016. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. Additional information is provided as Clinical Principles and Expert Opinions (table 2 in supplementary unabridged guideline, http://jurology.com/). RESULTS: The AUA (American Urological Association), ASTRO, and SUO (Society of Urologic Oncology) formulated an evidence-based guideline based on a risk stratified clinical framework for the management of localized prostate cancer. CONCLUSIONS: This guideline attempts to improve a clinician's ability to treat patients diagnosed with localized prostate cancer, but higher quality evidence in future trials will be essential to improve the level of care for these patients. In all cases, patient preferences should be considered when choosing a management strategy.
Authors: Vinay Prabhu; Andrew B Rosenkrantz; Ricardo Otazo; Daniel K Sodickson; Stella K Kang Journal: J Magn Reson Imaging Date: 2019-01-10 Impact factor: 4.813
Authors: Jeremie Calais; Amar U Kishan; Minsong Cao; Wolfgang P Fendler; Matthias Eiber; Ken Herrmann; Francesco Ceci; Robert E Reiter; Matthew B Rettig; John V Hegde; Narek Shaverdian; Chris R King; Michael L Steinberg; Johannes Czernin; Nicholas G Nickols Journal: J Nucl Med Date: 2018-04-13 Impact factor: 10.057
Authors: Channing J Paller; Emmanuel S Antonarakis; Tomasz M Beer; Hala T Borno; Maria I Carlo; Daniel J George; Julie N Graff; Shilpa Gupta; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Daniel P Petrylak; Matthew B Rettig; Charles J Ryan; Mary-Ellen Taplin; Young E Whang; Jacob Vinson; Heather H Cheng; Veda N Giri Journal: Clin Genitourin Cancer Date: 2019-04-18 Impact factor: 2.872
Authors: Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler Journal: J Clin Oncol Date: 2018-10-11 Impact factor: 44.544
Authors: S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: Sophie Knipper; Cristina Dzyuba-Negrean; Carlotta Palumbo; Angela Pecoraro; Giuseppe Rosiello; Zhe Tian; Alberto Briganti; Fred Saad; Derya Tilki; Markus Graefen; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2019-09-21 Impact factor: 2.370